4144 Organometallics, Vol. 16, No. 19, 1997
Albe´niz et al.
16: 1H NMR (CDCl3, δ, 300 MHz), 5.17 (t, J ) 11.1 Hz, 1H,
H3), 3.77 (m, J ) 11.1 Hz, 2H, H2, H4), 1.45-1.95 (m, 4H, H5,
H6), 1.40 (d, J ) 6.4 Hz, 3H, H1), 0.89 (t, J ) 7.3 Hz, 3H, H7).
17: 19F NMR (CDCl3, δ, 282 MHz), -163.3 (m, Fmeta), -158.3
(t, Fpara), -144.8 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.8
(m, 1H, H2)*, 5.46-5.53 (m, 2H, H5, H6), 4.9-5.05 (m, 2H, H1)*,
3.38 (d, J ) 5.3 Hz, 2H, H7), 2.1 (m, 4H, H3, H4); MS (EI) m/z
(relative intensity) 262 (M+, 2), 181 (13), 81 (100), 79 (64), 67
(18), 54 (23), 53 (44), 51 (12), 41 (62); (*) overlapped with
signals of other compounds.
18: 19F NMR (CDCl3, δ, 282 MHz), -163.5 (m, Fmeta), -158.4
(t, Fpara), -144.5 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.8
(m, 1H, H2)*, 5.4-5.45 (m, 2H, H4, H5), 4.9-5.05 (m, 2H, H1)*,
2.76 (t, J ) 7.2 Hz, 2H, H7), 2.71 (m, J ) 5.0, 2.0 Hz, 2H, H3),
2.28 (td, J ) 7.2, 5.9 Hz, 2H, H6); MS (EI) m/z (relative
intensity) 262 (M+, 1), 221 (6), 181 (39), 151 (7), 81 (100), 79
(14), 53 (14), 51 (9), 41 (33); (*) overlapped with signals of other
compounds.
19: 19F NMR (CDCl3, δ, 282 MHz), -163.9 (m, Fmeta), -158.3
(t, Fpara), -144.3 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 6.54
(dt, J ) 16.2, 7.0 Hz, 1H, H2), 6.27 (d, J ) 16.2 Hz, 1H, H1),
5.8 (m, 1H, H6)*, 4.9-5.05 (m, 2H, H7)*, 2.33 (m, 2H, H3), 2.14
(m, 2H, H5), 1.68 (qi, J ) 7.4 Hz, 2H, H4); MS (EI) m/z (relative
intensity) 262 (M+, 4), 181 (23), 81 (63), 79 (66), 77 (17), 67
(59), 65 (24), 54 (50), 53 (44), 51 (22), 41 (100); (*) overlapped
with signals of other compounds.
Reaction s with 1,7-Octadien e. An NMR tube was charged
with [PdPfBr(NCMe)2] (0.025 g, 0.0574 mmol) and CDCl3 (0.5
mL) and then cooled to -40 °C. 1,7-Octadiene (0.0085 mL,
0.0574 mmol) was added, and the reaction was monitored by
19F NMR. The temperature was increased in 10 °C steps, and
the different isomerization processes were observed. The
spectra showed that the reaction was complete after 3 h at
293 K, and the final mixture was analyzed by 1H and 19F NMR
and found to contain 23 (39%), 24 (25%), 25 (17%), and 26
(8%), plus unknown organic (5%) and organometallic (6%)
compounds (each one less than 2%). The yields in parentheses
are based on the integration of 19F NMR signals.
H7)*, 0.88 (t, J ) 6.8 Hz, 3H, H8); (*) overlapped with signals
of other compounds.
25: 19F NMR (CDCl3, δ, 282 MHz), -162.9 (m, Fmeta), -157.5
(t, Fpara), -143.9 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.07
(t, J ) 11.0 Hz, 1H, H4), 3.8 (m, J ) 11.0 Hz, 1H, H5)*, 3.64
(m, J ) 11.0 Hz, 1H, H3)*, 2.98-2.83 (m, 2H, H1)*, 2.16 (m,
1H, H2), 1.90 (m, 1H, H2′)*, 1.78-1.28 (m, 4H, H6, H7)*, 0.91
(t, J ) 6.7 Hz, 3H, H8); (*) overlapped with signals of other
compounds.
26: 19F NMR (CDCl3, δ, 282 MHz), -163.5 (m, Fmeta), -158.8
(t, Fpara), -145.2 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.37
(bs, 1H, H2), 2.68 (t, J ) 7.3 Hz, 2H, PfCH2), 2.2-2.4 (m, 3H,
H3, H5), 2.14 (m, 1H, H4), 1.85 (m, 1H, PfCH2CH H′), 1.66 (m,
3H, Me), 1.60 (m, 1H, H4′), 1.38 (m, 1H, PfCH2CHH′); MS (EI)
m/z (relative intensity) 276 (M+, 2), 95 (23), 81 (100), 79 (22),
67 (10), 53 (10), 41 (9).
27: 1H NMR (CDCl3, δ, 300 MHz), 5.25 (m, 1H, H2)*, 3.93
(d, J ) 7.2 Hz, 1H, H1syn), 3.90 (m, 1H, H3)*, 2.83 (d, J ) 11.9
Hz, 1H, H1anti)*, 1.96-1.28 (m, 8H, H4, H5, H6, H7)*, 1.11 (t, J
) 7.5 Hz, 3H, H8);3b (*) overlapped with signals of other
compounds.
28: 1H NMR (CDCl3, δ, 300 MHz), 5.17 (t, J ) 10.5 Hz, 1H,
H3), 3.8 (m, J ) 10.5 Hz, 2H, H2, H4)*, 1.96-1.28 (m, 6H, H5,
H6, H7)*, 1.40 (d, J ) 6.0 Hz, 3H, H1), 0.88 (t, J ) 6.8 Hz, 3H,
H8)*;3b (*) overlapped with signals of other compounds.
29: 19F NMR (CDCl3, δ, 282 MHz), -163.2-163.7 (m, Fmeta),
-158.6 (t, Fpara), -144.8 (m, Fortho); 1H NMR (CDCl3, δ, 300
MHz), 5.78 (m, 1H, H2)*, 5.35-5.55 (m, 2H, H5, H6)*, 4.95 (m,
2H, H1)*, 2.75 (t, J ) 7.3 Hz, 2H, H8), 2.3 (m, 2H, H7)*, 1.95-
2.1 (m, 4H, H3, H4)*; MS (EI) m/z (relative intensity) 276 (M+,
0.2), 181 (100), 95 (91), 67 (40), 54 (12), 41 (33); (*) overlapped
with signals of other compounds.
30: 19F NMR (CDCl3, δ, 282 MHz), -163.2-163.7 (m, Fmeta),
-158.4 (t, Fpara), -144.4 (m, Fortho); 1H NMR (CDCl3, δ, 300
MHz), 5.78 (m, 1H, H2)*, 5.35-5.55 (m, J ) 5.4 Hz, 2H, H6,
H7)*, 4.95 (m, 2H, H1)*, 3.37 (d, J ) 5.4 Hz, 2H, H8), 1.95-2.1
(m, J ) 7.2 Hz, 4H, H3, H5)*, 1.44 (qi, J ) 7.2 Hz, 2H, H4); MS
(EI) m/z (relative intensity) 276 (M+, 2), 234 (19), 219 (20),
181 (83), 95 (100), 82 (22), 67 (47), 55 (93), 54 (44), 53 (21), 41
(37); (*) overlapped with signals of other compounds.
31: 19F NMR (CDCl3, δ, 282 MHz), -164.0 (m, Fmeta), -158.4
(t, Fpara), -144.3 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 6.54
(dt, J ) 15.9, 6.6 Hz, 1H, H2), 6.26 (d, J ) 15.9 Hz, 1H, H1),
5.78 (m, 1H, H7)*, 4.95 (m, 2H, H8)*, 2.3 (m, J ) 6.6 Hz, 2H,
H3)*, 1.95-2.1 (m, 2H, H6)*, 1.6 (m, 4H, H4, H5); MS (EI) m/z
276 (M+); (*) overlapped with signals of other compounds.
32: 19F NMR (CDCl3, δ, 282 MHz), -163.2-163.7 (m, Fmeta),
-158.7 (t, Fpara), -144.8 (m, Fortho); 1H NMR (CDCl3, δ, 300
MHz), 5.35-5.55 (m, 4H, H2, H3, H5, H6)*, 2.71 (t, J ) 7.3 Hz,
2H, H8), 2.7 (m, 2H, H4), 2.3 (m, 2H, H7)*, 1.66 (m, 3H, H1)*;
MS (EI) m/z 276 (M+); (*) overlapped with signals of other
compounds.
When the reaction was carried out with a larger amount of
starting materials, column chromatography (silica gel) could
be used to separate the organic compounds obtained, eluting
with n-hexane. Further verification and assignment of spectra
for the palladium complexes and 26 were accomplished by 1H-
1H COSY experiments and (for 26) GC-MS. Attempts at
isolation as solids of the organometallic compounds failed due
to their high solubility.
Excess 1,7-octadiene (0.085 mL, 0.575 mmol) was added to
[PdPfBr(NCMe)2] (0.050 g, 0.115 mmol) in CDCl3 (0.6 mL). The
reaction was complete after 2 h at room temperature as shown
by 19F NMR. A mixture containing 23 (15%), 24 (9%), 25 (7%),
27 (9%), 28 (25%), 26 (4%), 29 (9%), 30 (7%), 31 (2%), 32 (3%),
33 (4%), and unknown organics (4%) and organometallics (2%)
was obtained. The organic compounds could be separated by
column chromatography. Assignment of 1H NMR spectra was
33: 19F NMR (CDCl3, δ, 282 MHz), -163.2-163.7 (m, Fmeta),
-158.5 (t, Fpara), -144.4 (m, Fortho); 1H NMR (CDCl3, δ, 300
MHz), 5.35-5.55 (m, 4H, H2, H3, H6, H7)*, 3.43 (d, J ) 6.2 Hz,
2H, H1), 1.95-2.1 (m, 4H, H4, H5)*, 1.66 (m, 3H, H8)*; MS (EI)
m/z (relative intensity) 276 (M+, 7), 194 (10), 181 (94), 95 (91),
82 (30), 81 (24), 67 (56), 55 (100), 54 (44), 53 (23), 41 (38); (*)
overlapped with signals of other compounds.
1
accomplished by using H-1H COSY.
20: 19F NMR (CDCl3, δ, 243 K, 282 MHz), -161.6 (m, Fmeta),
-156.7 (t, Fpara), -142.8 (m, Fortho).
21: 19F NMR (CDCl3, δ, 243 K, 282 MHz), -162.6 (m, Fmeta),
-157.8 (t, Fpara), -144.5 (m, Fortho).
22: 19F NMR (CDCl3, δ, 263 K, 282 MHz), -163.1 (m, Fmeta),
-158.4 (t, Fpara), -144.4 (m, Fortho).
23: 19F NMR (CDCl3, δ, 282 MHz), -163.4 (m, Fmeta), -158.6
(t, Fpara), -144.8 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.25
(m, 1H, H2), 3.94 (d, J ) 6.6 Hz, 1H, H1syn), 3.90 (m, 1H, H3),
2.83 (d, J ) 11.9 Hz, 1H, H1anti)*, 2.68 (t, J ) 7.5 Hz, 2H, H8),
1.96-1.50 (m, 8H, H4, H5, H6, H7)*; (*) overlapped with signals
of other compounds.
24: 19F NMR (CDCl3, δ, 282 MHz), -162.3 (m, Fmeta), -156.7
(t, Fpara), -143.4 (m, Fortho); 1H NMR (CDCl3, δ, 300 MHz), 5.27
(t, J ) 11.3 Hz, 1H, H3), 3.8 (m, J ) 11.3 Hz, 1H, H4)*, 3.64
(m, J ) 11.3 Hz, 1H, H2)*, 3.30 (dd, J ) 14.4, 4.4 Hz, 1H, H1),
3.03 (dd, J ) 14.4, 9.7 Hz, 1H, H1′), 1.96-1.28 (m, 6H, H5, H6,
Ack n ow led gm en t. This work was supported by the
Direccio´n General de Investigacio´n Cient´ıfica y Te´cnica
(Spain) (Project PB96-0363), the Commission of the
European Communities (Network “Selective Processes
and Catalysis Involving Small Molecules”, CHRX-CT93-
0147), and the J unta de Castilla y Leo´n (Project VA 40-
96). Y.-S.L. thanks the Spanish Ministerio de Educacio´n
y Ciencia and the AECI/ICDsUniversidad de Valladolid
for fellowships.
OM9703907